Alemtuzumab (Campath)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Anti-CD52 antibody that is believed to cause antibody-dependent cell-mediated cytotoxicity of cells that express the CD52 antigen on their surface: B and T lymphocytes, most monocytes, macrophages, natural killer (NK) cells, and a subpopulation of granulocytes.[1][2][3]
Route: IV
Extravasation: neutral

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Brand names: Campath, Campath-1H, Lemtrada, Mabcampath


  1. 1.0 1.1 1.2 Alemtuzumab (Campath) package insert
  2. Alemtuzumab (Campath) package insert (locally hosted backup)
  3. Campath manufacturer's website
  4. Alemtuzumab (Campath) patient drug information (Chemocare)
  5. Alemtuzumab (Campath) patient drug information (UpToDate)
  6. FDA approval letter dated May 7th, 2001
  7. Alemtuzumab for multiple sclerosis